The UVA Cancer Center has a clinical trial for adults ages 18 and over who have endometrial, non-small cell lung, ovarian, primary peritoneal or fallopian tube cancer.
The purpose of the phase 1 portion of this study (Dose Escalation) is to study and identify the highest tolerable safe dose of the study drug, MORAb-202. Not all subjects will get the same dose of the study drug. At the beginning of the study a small group of three to six subjects will receive an infusion with a low dose of the study drug. If this dose does not cause severe side effects, it will be increased for each new group of subjects who participate in the study and will continue until the highest tolerable safe dose of the study drug is confirmed.
The purpose of the Phase 2 (Dose Expansion) is to further investigate how the different tumor types being studied respond to the study drug and to gather more information on its safety and effectiveness.
The overall trial does not have a set duration, study treatment will continue for as long as your study doctor thinks the medicine is helping you or another reason for discontinuation has been presented. Post-treatment, the study team will conduct follow-up visits via telephone every 12 weeks for up to 3 years. At this time, the participant will be asked about his/her general well-being as well as any other anticancer medications(s) he/she may be taking.
Research-specific tests will be provided at no cost to you. The costs of standard tests, procedures, and treatment of complications will be paid by your insurer in the same way as if you were not part of this study. You may be responsible for any extra costs your insurance company does not pay.
You will get paid $50 per visit and reimbursed up to $175 for hotel stays per night, if required for the study. Payment will be after study visits (schedule dependent on frequency).